StockTipsArenaBeta

BUY Mankind Pharma Limited — Somil Mehta, Sharekhan

BUYMankind Pharma Limited

bySomil Mehta, SharekhanHorizon: 1–3 months7 May 2026via CNBC Awaaz.

Entry₹2,381.8Inferred
Target₹2,600
Total upside +9.16% (call closed)
Stop loss₹2,280-4.27% risk
Exit₹2,60020 May 2026, 12:05 pm
Target hit+9.16%0.00%upside left
Follow Somil Mehta for new calls(37% target hit, 43 closed calls)Get alertsWatch MANKIND for new buy/sell callsGet alertsSee 2 active Short-term calls on MANKINDSee 28 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 8 Sept, 3:24 pm IST
3 supporting3 neutral0 opposing
Supports the BUY call (3)

Mankind Pharma announced its Q4FY26 and FY26 financial results. Revenue increased by 11.8% YoY to INR 3,443 Cr in Q4FY26, with Adj. EBITDA margin at 27.1%. FY26 revenue grew 17.0% to INR 14,278 Cr.

NSE · Press Release·19 May · today

(opens in new tab)

Mankind Pharma reported Q4FY26 & FY26 financial results. Revenues increased 11.8% YoY to INR 3,443 Cr in Q4FY26 and 17.0% YoY to INR 14,278 Cr in FY26. Adj. EBITDA margin was 27.1% in Q4FY26.

BSE · Company Update·19 May · today

(opens in new tab)

1 advisor has an active long-term BUY call on this stock

Advisor consensus · adjacent horizon·29 Apr · 3w ago

Neutral / worth noting (3)

Please find attached Audited Financail Results for the quarter and year ended March 31, 2026

BSE · Board Meeting·19 May · today

(opens in new tab)

Mankind Pharma Limited has received credit ratings from CARE Ratings Limited for its long-term/short-term bank facilities amounting to ₹1,000 crore. The ratings assigned are CARE AA+ (Stable) for long

NSE · Credit Rating- New·22 Apr · 4w ago

(opens in new tab)

Mankind Pharma Ltd has attached an intimation regarding credit ratings assigned by CARE Ratings Limited.

BSE · Company Update·22 Apr · 4w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.